Funding Links #1
Scheme | Details | Typical timelines and budget |
AZ Open Innovation | Access AZ screening library against target of interest. | Compounds supplied by AstraZeneca, screening run by partner |
BHF Translational Award | Supports the pre-clinical development of new cardiovascular medicines and technologies so that they are attractive for follow-on funding: bridging the funding gap between promising innovations and the clinic | £750k. |
CRUK Innovation Prize | Develop the translational and commercial potential of research | One year, £50k |
CRUK Small Molecule Drug Discovery Project Awards | Identify and characterise small molecule novel therapeutic targets and to identify and develop novel therapeutic entities for the benefit of cancer patients. New target identification & validation. | One to three years, £100k p.a. |
European Lead Factory | Access 300k (to 500k) 'lead-like' compounds to screen against a novel target (phenotypic screens accepted). Generates qualified hit list of up to 50 compounds. Must be in 384 format or demonstrate feasibility to be converted to 384. |
Work carried out by European Lead Factory |
GSK Discovery Fast Track | Screening service against target of interest. Not always open. |
As required to progress project |
Innovate UK | Multiple schemes which are updated regularly, ranging from small innovation vouchers to large, collaborative programmes. Usually industry-led. | Various |
Merck Biopharma Mini-library | Mini Library contains former Merck Biopharma research and development compounds and their derivatives: use these compounds in your assay systems. | Compounds supplied by Merck, screening run by partner |
MRC/AstraZeneca Centre for Lead Discovery | The MRC/AstraZeneca Centre for Lead Discovery (CLD) aims to support academic researchers in discovering potential starting points for small molecule therapeutic approaches with a clear line-of-sight to therapeutic use. | Cost of screen are covered |
MRC/UCB Antibody Discovery Initiative (ADI) | The MRC/UCB Antibody Discovery Initiative aims to support academic researchers seeking to develop antibody-based therapeutics. It is intended to accelerate the transition from discovery research to translational development projects by enabling generation of novel antibodies suitable for testing in models of disease. A clear line-of-sight to therapeutic use will be required to secure funding. | Cost of screen are covered |
MRC Biomedical catalyst | Early stage, small molecule, drug discovery. Will fund development of therapeutics. | Up to three years, £3M |
Wellcome Trust Innovator Awards | For the development of healthcare innovations that could have a significant impact on human health. | Up to two years, £500k (£750k for multidisciplinary projects) |